Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor

Park, Inkeun; Lee, Jae-Lyun; Ahn, Jin-Hee; Lee, Dae-Ho; Lee, Kyoo-Hyung; You, Dalsan; Jeong, In; Song, Cheryn; Hong, Bumsik; Hong, Jun; Ahn, Hanjong
May 2015
Cancer Chemotherapy & Pharmacology;May2015, Vol. 75 Issue 5, p1025
Academic Journal
Purpose: To assess the efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for metastatic renal cell carcinoma (mRCC) patients and to identify predictive factors for increased progression-free survival (PFS) or overall survival (OS). Methods: The clinicopathological features, outcomes, and prognostic factors of mRCC patients who were treated with VEGFR-TKI after treatment failure using both VEGFR-TKIs and mTOR inhibitors (mTORi) were reviewed. Results: A total of 29 eligible patients were included. Five (17 %) patients achieved partial response (PR) with a median response duration of 9.5 months (95 % CI 5.7-13.4 months), and additional 16 patients (55 %) achieved stable disease. With a median follow-up period of 19.2 months (95 % CI 18.9-19.6 months), the median PFS and OS were 3.0 months (95 % CI 1.1-4.9 months) and 4.9 months (95 % CI 2.9-6.8 months), respectively. In univariate analysis, the best response to first-line VEGFR-TKI (PR vs. non-PR, p < 0.001) and time to rechallenge (TTR, ≤12 months vs. between 12 and 24 months vs. >24 months, p = 0.005) were identified as predictive factors for longer PFS on VEGFR-TKI rechallenge. In addition, an MSKCC risk group (intermediate- vs. poor-risk group, p = 0.027), better response at first-line VEGFR-TKI (PR vs. non-PR, p = 0.003), and TTR (≤12 months vs. between 12 and 24 months vs. >24 months, p = 0.026) were identified as prognostic factors for longer OS. Conclusions: VEGFR-TKI rechallenge may be a viable option for select metastatic RCC patients who fail both VEGFR-TKI and mTORi therapies.


Related Articles

  • Sorafenib in Renal Cell Carcinoma: Decision Algorithm. Vázquez, Sergio; León, Luis; Lázaro, Martín // Cancer & Chemotherapy Reviews;Apr-Jun2014, Vol. 9 Issue 2, p61 

    Molecular-targeted therapy with multikinase inhibitors has been recommended as first-choice therapy in advanced renal cell carcinoma. Sorafenib is a tyrosine kinase inhibitor able to inhibit vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and Raf kinase,...

  • Possible Prognostic and Therapeutic Significance of c-Kit Expression, Mast Cell Count and Microvessel Density in Renal Cell Carcinoma. Marech, Ilaria; Gadaleta, Cosmo Damiano; Ranieri, Girolamo // International Journal of Molecular Sciences;Jul2014, Vol. 15 Issue 7, p13060 

    Renal cell carcinoma (RCC) is the most frequent renal tumor and its incidence is increasing worldwide. Tumor angiogenesis is known to play a crucial role in the etiopathogenesis of RCC and over the last few years an even deeper knowledge of its contribution in metastatic RCC development has led...

  • Effect of axitinib on the QT interval in healthy volunteers. Ruiz-Garcia, Ana; Houk, Brett; Pithavala, Yazdi; Toh, Melvin; Sarapa, Nenad; Tortorici, Michael // Cancer Chemotherapy & Pharmacology;Mar2015, Vol. 75 Issue 3, p619 

    Purpose: Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1-3, approved for second-line treatment of advanced renal cell carcinoma (RCC). Preclinical studies did not indicate potential for axitinib-induced delayed cardiac repolarization. Methods: The...

  • Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. Narayan, Vivek; Haas, Naomi Balzer // International Journal of Nephrology & Renovascular Disease;Mar2016, Vol. 9, p65 

    Background: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the...

  • Temsirolimus.  // Reactions Weekly;Jun2014, Vol. 1507 Issue 1, p29 

    An abstract of the article "Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors," by S. Weikert and colleagues is presented.

  • Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor. Kwonoh Park; Jae-Lyun Lee; Jin-Hee Ahn; Kyoo Hyung Lee; In-Gab Jeong; Cheryn Song; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn // Cancer Research & Treatment;2014, Vol. 46 Issue 4, p339 

    Purpose The purpose of this study is to assess the efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC) for whom initial treatment with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) has failed. Materials and...

  • Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study. Merchan, Jaime; Qin, Rui; Pitot, Henry; Picus, Joel; Liu, Glenn; Fitch, Tom; Maples, William; Flynn, Patrick; Fruth, Briant; Erlichman, Charles // Cancer Chemotherapy & Pharmacology;Mar2015, Vol. 75 Issue 3, p485 

    Purpose: Bevacizumab or temsirolimus regimens have clinical activity in the first-line treatment of advanced renal cell carcinoma (RCC). This phase I/II trial was conducted to determine the safety of combining both agents and its efficacy in RCC patients who progressed on at least one prior...

  • Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication. Socola, Francisco; Loaiza-Bonilla, Arturo; Benedetto, Pasquale // Case Reports in Oncological Medicine;2012, p1 

    We report a case of a Caucasian male with a history of renal cell carcinoma metastatic (mRCC) to the lungs refractory despite aggressive treatment with several lines of targeted therapy. He was started on axitinib palliative targeted therapy with a good clinical and radiological response;...

  • EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. Davis, I. D.; Long, A.; Yip, S.; Espinoza, D.; Thompson, J. F.; Kichenadasse, G.; Harrison, M.; Lowenthal, R. M.; Pavlakis, N.; Azad, A.; Kannourakis, G.; Steer, C.; Goldstein, D.; Shapiro, J.; Harvie, R.; Jovanovic, L.; Hudson, A. L.; Nelson, C. C.; Stockler, M. R.; Martin, A. // Annals of Oncology;Jun2015, Vol. 26 Issue 6, p1118 

    Background: We hypothesised that alternating inhibitors of the vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin pathways would delay the development of resistance in advanced renal cell carcinoma (aRCC). Patients and methods: A single-arm, two-stage,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics